Novo Nordisk stock slipped 2% to 75.33, while Lilly shares rose 3.3% to 864.90. 15% Body Weight Over 12 Weeks United Biotechnology recently wrapped a Phase 1 study of UBT251 in 36 patients.

Novo Nordisk’s share price fell on the news, trading 0.8% lower after being 4% higher earlier in the day. The shares are down 32% year-to-date and 59% from their all-time high. 4 ...

Novo Nordisk's stock has plummeted over 60%, while also arguably losing market share to Eli Lilly. Click here to find out why NVO stock is a Buy.

Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, ... The way that we think about this is that we have three sets of data to look at from a modeling perspective.

Novo Nordisk (NYSE: NVO) stock jumped 3% through 10:55 a.m. Tuesday on some potentially positive news in the GLP-1 weight loss market.. As Reuters reports today, an online weight loss company ...

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say the company's cautious culture is to blame.

Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.

Novo Nordisk is partnering with online telehealth companies to sell a direct-to-consumer, lower cost version of its popular weight-loss drug Wegovy. The pharmaceutical company announced it would ...

Novo’s weight-loss drugs are administered by injection and a pill version would be more convenient for patients, ... Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills.

Danish pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down by “mutual agreement” with the company’s board of directors ...

Wegovy-maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.